{
    "clinical_study": {
        "@rank": "58913", 
        "brief_summary": {
            "textblock": "To assess the safety and pharmacokinetics of single oral doses of 524W91 administered in\n      HIV-infected patients. To determine the effects of food on bioavailability of 524W91."
        }, 
        "brief_title": "The Safety and Effectiveness of 524W91", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to receive six single escalating doses of 524W91 or placebo, with\n      each dose separated by at least a 6-day washout interval. In the time between 2 of the\n      doses, the effect of food on pharmacokinetics will be investigated, with one dose\n      administered in conjunction with a high-fat meal and one dose administered in a fasted\n      state."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients must have:\n\n          -  Documented HIV infection.\n\n          -  CD4 count >= 200 cells/mm3.\n\n          -  No active opportunistic infection.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms or conditions are excluded:\n\n          -  Malignancy or other condition that would confound study assessment or interfere with\n             ability to complete the study.\n\n          -  Malabsorption syndrome or other gastrointestinal dysfunction that might interfere\n             with gastrointestinal absorption.\n\n        Concurrent Medication:\n\n        Excluded on the day of each dose:\n\n          -  Antiretrovirals.\n\n          -  Any prescription or over-the-counter medication.\n\n          -  Alcoholic beverages.\n\n          -  Coffee, tea, and other xanthine-containing beverages and foods.\n\n        Patients with the following prior conditions are excluded:\n\n        History of hepatitis, pancreatitis, or cardiomyopathy within the past 5 years.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Antiretrovirals within 24 hours prior to each dose.\n\n          -  Any prescription or over-the-counter medications within 48 hours prior to each dose.\n\n          -  Alcoholic beverages within 48 hours prior to each dose. Current alcohol or illicit\n             drug use that may affect patient compliance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "18", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002335", 
            "org_study_id": "233A"
        }, 
        "intervention": {
            "intervention_name": "Emtricitabine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Emtricitabine"
        }, 
        "keyword": [
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Antiviral Agents"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Francisco", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94103"
                }, 
                "name": "ViRx Inc"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Phase I, Randomized, Single-Dose, Placebo-Controlled Trial to Evaluate the Safety and Pharmacokinetics of 524W91", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002335"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Glaxo Wellcome", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 1996"
    }, 
    "geocoordinates": {
        "ViRx Inc": "37.775 -122.419"
    }
}